Evelo biosciences, inc. (EVLO)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Mar'17
Operating activities
Net loss

0

-

0

0

0

-

0

0

0

-

Net Income (Loss) Attributable to Parent

-

-

-

-

-

-

-

-

-

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

8,167

8,165

7,715

7,248

7,360

6,059

0

0

0

0

Depreciation expense

1,864

1,764

1,564

1,403

1,700

1,900

0

0

0

0

Change in fair value of warrant and debt derivative liability

-

-

-

-

-

406

0

0

0

0

Net (accretion of discount)/amortization of premium on marketable securities

49

164

164

161

115

0

0

0

0

-

Non-cash interest expense

277

255

288

103

114

103

0

0

0

0

Non-cash lease expense

0

-

-

-

-

-

-

-

-

-

Gain on sale of fixed assets, net

0

-

-

-

0

-

-

-

-

-

Changes in assets and liabilities:
Prepaid expenses and other current assets

-891

-372

505

1,753

2,928

3,052

0

0

0

0

Accounts payable

-117

-585

-1,506

1,290

-80

-221

0

0

0

0

Accrued expenses and other current liabilities

3,655

3,694

2,187

2,326

3,126

3,594

0

0

0

0

Operating lease liabilities

0

-

-

-

-

-

-

-

-

-

Other liabilities

0

-

-

-

0

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

0

0

0

0

Net cash used in operating activities

-73,502

-71,980

-68,442

-61,465

-56,956

-47,279

0

0

0

0

Investing activities
Proceeds from sales and maturities of investments

24,000

55,000

136,250

132,250

112,250

81,250

0

0

0

-

Purchases of property and equipment

2,591

3,032

3,804

4,279

5,338

5,462

0

0

0

0

Proceeds from sale of fixed assets

0

-

-

-

0

-

-

-

-

-

Net cash (used in)/provided by investing activities

21,417

51,970

81,014

-7,945

-29,004

-60,128

0

0

0

0

Financing activities
Deferred issuance costs

-

-

-

-

-

0

0

0

0

-

Net proceeds from the issuance of convertible preferred stock

-

-

-

-

-

81,336

0

0

0

0

Proceeds from Issuance of Long-term Debt

-

-

-

-

-

4,975

0

0

0

-

Proceeds from the exercise of stock options

479

511

300

282

344

122

0

0

0

0

Net cash provided by financing activities

4,960

4,992

4,781

-267

76,889

162,012

0

0

0

0

Net (decrease) increase in cash, cash equivalents and restricted cash

-47,125

-15,018

17,353

-69,677

-9,071

54,605

0

0

0

-

Net increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

0

Supplemental disclosure of cash flow information
Cash paid for interest

1,388

1,166

935

844

814

742

0

0

0

0

Noncash investing and financing activities
Property and equipment additions in accounts payable and accrued expenses

480

246

462

-530

-82

348

0

0

0

0

Issuance of warrants in connection with long-term debt facility

-

-

-

-

-

89

0

0

0

-

Accrued non-cash deferred offering costs

-

-

-

-

-

-

-

-

0

-

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

0